共 100 条
[1]
Smith MR(2007)Androgen deprivation therapy for prostate cancer: new concepts and concerns Curr Opin Endocrinol Diabetes Obes 14 247-254
[2]
Shahinian VB(2005)Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 154-164
[3]
Kuo Y(1999)The structural basis of bone fragility in men Bone 25 143-147
[4]
Freeman JL(2002)Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy J Urol 167 2361-2367
[5]
Goodwin JS(1999)Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostate carcinoma J Urol 161 1219-1222
[6]
Seeman E(2000)Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 181-186
[7]
Berruti A(1998)The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy Cancer 83 1561-1566
[8]
Dogliotti L(2005)Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 7897-7903
[9]
Terrone C(1999)Prostate cancer practice patterns and quality of life: The Prostate Cancer Outcomes Study J Natl Cancer Inst 91 1719-1724
[10]
Cerutti S(2000)Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study J Natl Cancer Inst 92 1582-1592